Kinnate Biopharma Inc. (KNTE)
NASDAQ: KNTE
· Real-Time Price · USD
2.65
-0.01 (-0.38%)
At close: Apr 02, 2024, 10:00 PM
Kinnate Biopharma Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 57M | 51.66M | 34.51M | 73.57M | 29.26M | 34.5M | 35.06M | 33.1M | 116.1M | 135.01M | 132.99M | 182.39M |
Short-Term Investments | 97.04M | 115.91M | 150.2M | 127.41M | 172.21M | 196.48M | 197.93M | 206.16M | 103.36M | 88.22M | 87.02M | 65.81M |
Long-Term Investments | 10.63M | 12.76M | 19.58M | 30.2M | 39.14M | 31.1M | 46.6M | 63.13M | 105.45M | 124.64M | 145.14M | 134.91M |
Other Long-Term Assets | 38K | 2.52M | 2.33M | 2.34M | 2.4M | 3.11M | 3.09M | 3.1M | 1.77M | 690K | 461K | n/a |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 4.14M | 2.73M | 3.9M | 4.31M | 3.64M | 3.73M | 34.14M | 4.93M | 5.64M | 3.18M | 38.77M | 2.98M |
Total Current Assets | 158.18M | 170.3M | 188.6M | 205.29M | 230.84M | 261.18M | 267.13M | 275.2M | 258.69M | 260.71M | 258.78M | 251.17M |
Property-Plant & Equipment | 4.76M | 5.13M | 5.63M | 6.05M | 6.45M | 6.75M | 7.07M | 7.19M | 956K | 291K | 286K | 283K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 15.43M | 20.41M | 27.54M | 38.59M | 47.99M | 40.96M | 56.76M | 73.42M | 108.17M | 125.62M | 145.88M | 135.19M |
Total Assets | 173.6M | 190.71M | 216.13M | 243.88M | 278.83M | 302.13M | 323.9M | 348.62M | 366.86M | 386.33M | 404.66M | 386.37M |
Account Payables | 2.03M | 2.93M | 2.7M | 4.45M | 2.97M | 3.06M | 2.02M | 4.42M | 3.15M | 2.72M | 1.33M | 3.21M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 892K | 869K | 959K | 983K | 991K | 966K | 836K | 454K | n/a | n/a | n/a | n/a |
Other Current Liabilities | 9.07M | 11.98M | 12.12M | 12.72M | 13.21M | 11.32M | 8.61M | 8.78M | 9.24M | 7.58M | 6.99M | 4.58M |
Total Current Liabilities | 11.99M | 15.77M | 15.77M | 18.16M | 17.17M | 15.34M | 11.46M | 13.66M | 12.39M | 10.3M | 8.32M | 7.79M |
Long-Term Debt | 2.28M | 2.52M | 2.74M | 2.96M | 3.19M | 3.45M | 3.7M | 4.14M | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 2.28M | 2.52M | 2.74M | 2.96M | 3.19M | 3.45M | 3.7M | 4.14M | 35M | 35M | 35M | n/a |
Total Liabilities | 14.28M | 18.29M | 18.52M | 21.12M | 20.36M | 18.79M | 15.17M | 17.8M | 12.39M | 10.3M | 8.32M | 7.79M |
Total Debt | 3.17M | 3.38M | 3.7M | 3.95M | 4.18M | 4.42M | 4.54M | 4.6M | n/a | n/a | n/a | n/a |
Common Stock | 5K | 5K | 5K | 5K | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K |
Retained Earnings | -372.01M | -354.95M | -324.22M | -292.3M | -259.36M | -227.8M | -197.06M | -169.99M | -143.09M | -116.93M | -92.23M | -70.79M |
Comprehensive Income | -12K | -147K | -342K | -464K | -1.41M | -2.56M | -2.74M | -2.18M | -524K | -36K | -74K | -40K |
Shareholders Equity | 159.33M | 172.42M | 197.62M | 222.76M | 223.47M | 248.34M | 273.73M | 295.82M | 319.48M | 341.03M | 361.34M | 378.57M |
Total Investments | 107.67M | 128.68M | 169.78M | 157.61M | 211.35M | 227.57M | 244.53M | 269.3M | 208.81M | 212.85M | 232.15M | 200.72M |